Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TMPRSS2
REST API REST API
Homo sapiens
TMPRSS2 is differentially expressed in 254 experiments: 148 organism parts: lung, prostate, ... (146 more);, 177 disease states: normal, head and neck squamous cell carcinoma, ... (175 more);, 63 cell types 367 cell lines 29 compound treatments and 73 other conditions.
Synonyms PRSS10
Orthologs Tmprss2 (Mus musculus)   F1NY88_CHICK (Gallus gallus)   TMPRSS2 (Danio rerio)   A2VDV7_BOVIN (Bos taurus)   Tmprss2 (Rattus norvegicus)   ENSXETG00000000063 (Xenopus laevis)   ENSXETG00000027108 (Xenopus laevis)   ENSXETG00000031798 (Xenopus laevis)   ENSXETG00000031788 (Xenopus laevis)   ENSXETG00000025394 (Xenopus laevis)   tmprss2 (Xenopus laevis)   LOC100493729 (Xenopus laevis)   ENSXETG00000027103 (Xenopus laevis)   TMPRSS2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, cytoplasm, scavenger receptor activity, membrane, peptidase activity, extracellular region, serine-type peptidase activity, integral to plasma membrane, proteolysis, catalytic activity, serine-type endopeptidase activity
InterPro Term Peptidase_S1A, Peptidase_S1_S6, Srcr_rcpt, Srcr_rcpt-rel, Peptidase_S1A_nudel, LDrepeatLR_classA_rpt
UniProt Accession O15393, C9J5Y1, C9JB05, C9JKZ3, F8WES1
Search EB-eye ENSG00000184012
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-2549, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (29 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
SW480
3
E-MEXP-1014, E-GEOD-2509, E-MTAB-37
BT-474
2
E-GEOD-5823, E-GEOD-3529
H441
2
E-GEOD-16194, E-MTAB-62
LNCaP
2
E-GEOD-14464, E-GEOD-14990
361 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-993, ... (37 experiments)

Factor Value U/D Experiments
macrophage
3
E-GEOD-3982, E-GEOD-22373, E-GEOD-8286
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
human embryonic stem cell
1
2
E-GEOD-18147, E-GEOD-20033, E-GEOD-18265
primary fibroblast
1
E-MEXP-66
testis - germ cell
1
E-AFMX-5
CD133+ prostate epithelial cell
1
1
E-MEXP-993
57 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-MTAB-62, ... (53 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-GEOD-7307, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-7307
colon carcinoma
2
E-MTAB-37, E-GEOD-3726
control
2
E-GEOD-21912, E-GEOD-20602
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
171 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-15205, E-TABM-782, E-GEOD-12438, E-GEOD-5824, ... (20 experiments)

Factor Value U/D Experiments
none
3
4
E-GEOD-12438, E-GEOD-412, E-GEOD-5824, E-GEOD-4668, E-TABM-782, ... (7 experiments)
dihydrotestoterone
1
E-GEOD-7708
glucose
1
E-MEXP-941
RA
1
E-MEXP-2417
vanadium pentoxide
1
E-GEOD-5339
TNF
1
E-GEOD-15205
23 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
34 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-2171, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Date of sample preparation and hybridisation
studied in E-GEOD-22541

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-22541, E-GEOD-2509, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-17385, E-MTAB-108

Genotype
studied in E-MEXP-1996, E-GEOD-22056, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1446, E-GEOD-22278, E-MEXP-1103

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MEXP-2069, E-GEOD-1926, E-TABM-26, E-GEOD-20876, ... (34 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-980

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-1309

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

RNAi
studied in E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-GEOD-1561, E-GEOD-4922

Processing time: 0.459 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM